AU2015202413B2 - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents

Method for the preparation of human albumin with reduced level of dissolved oxygen Download PDF

Info

Publication number
AU2015202413B2
AU2015202413B2 AU2015202413A AU2015202413A AU2015202413B2 AU 2015202413 B2 AU2015202413 B2 AU 2015202413B2 AU 2015202413 A AU2015202413 A AU 2015202413A AU 2015202413 A AU2015202413 A AU 2015202413A AU 2015202413 B2 AU2015202413 B2 AU 2015202413B2
Authority
AU
Australia
Prior art keywords
albumin
solution
stage
dissolved oxygen
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015202413A
Other languages
English (en)
Other versions
AU2015202413A1 (en
Inventor
Montserrat Costa Rierola
Juan Ignacio Jorquera Nieto
Ana Maria Ortiz Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015202413(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols SA filed Critical Grifols SA
Publication of AU2015202413A1 publication Critical patent/AU2015202413A1/en
Application granted granted Critical
Publication of AU2015202413B2 publication Critical patent/AU2015202413B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2015202413A 2014-05-29 2015-05-06 Method for the preparation of human albumin with reduced level of dissolved oxygen Active AU2015202413B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430824 2014-05-29
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (2)

Publication Number Publication Date
AU2015202413A1 AU2015202413A1 (en) 2015-12-17
AU2015202413B2 true AU2015202413B2 (en) 2017-08-31

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015202413A Active AU2015202413B2 (en) 2014-05-29 2015-05-06 Method for the preparation of human albumin with reduced level of dissolved oxygen

Country Status (22)

Country Link
US (1) US10350274B2 (OSRAM)
EP (1) EP2952203B9 (OSRAM)
JP (3) JP2015224251A (OSRAM)
KR (1) KR101960729B1 (OSRAM)
CN (1) CN105315362B (OSRAM)
AR (1) AR100618A1 (OSRAM)
AU (1) AU2015202413B2 (OSRAM)
BR (1) BR102015012091A8 (OSRAM)
CA (1) CA2890642C (OSRAM)
CL (1) CL2015001446A1 (OSRAM)
ES (2) ES2524516B1 (OSRAM)
HU (1) HUE031823T2 (OSRAM)
IL (1) IL238898B (OSRAM)
MX (1) MX362869B (OSRAM)
MY (1) MY171771A (OSRAM)
NZ (1) NZ708537A (OSRAM)
PL (1) PL2952203T3 (OSRAM)
PT (1) PT2952203T (OSRAM)
RU (1) RU2657578C2 (OSRAM)
SG (1) SG10201504137PA (OSRAM)
TW (1) TWI607018B (OSRAM)
ZA (1) ZA201503539B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2975517T3 (es) 2016-04-28 2024-07-08 Alkahest Inc Fracciones de plasma como terapia para el cáncer de timo
SG11201901273TA (en) 2016-08-18 2019-03-28 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN117899111A (zh) 2017-04-26 2024-04-19 万能溶剂有限公司 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案
KR20210024196A (ko) 2018-07-20 2021-03-04 알카헤스트 인코포레이티드 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법
UA128648C2 (uk) 2018-10-26 2024-09-18 Алкахест, Інк. Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
CA3151943A1 (en) 2019-11-04 2021-05-14 Viktoria Kheifets Blood plasma fractions for use in muscle regeneration
EP4061384A4 (en) 2019-11-20 2023-11-01 Alkahest, Inc. BLOOD PLASMA FRACTIONS FOR USE IN LIVER REGENERATION
JP2026511640A (ja) 2023-03-29 2026-04-14 グリフォルス・ワールドワイド・オペレーションズ・リミテッド ＦｃεＲＩβ自己抗体のレベルが低減された血漿製剤の組成物および調製方法
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
JP4225416B2 (ja) * 2001-06-29 2009-02-18 旭化成ファーマ株式会社 タンパク質製剤の安定性を改善する方法
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
ATE342904T1 (de) * 2003-08-28 2006-11-15 Nipro Corp Künstlicher sauerstoffträger und herstellungsverfahren dafür
RS52459B (sr) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. Stabilizovane kompozicije glukocerebrozidaze
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAYASHI, T. et al. The importance of sample preservation temperature for analysis of the redox state of human serum albumin. Clinica Chimica Acta. Febrero 2002, Vol. 316, N 1-2, páginas: 175 - 178. *
MARIE, A.-L. et al. Analytica Chimica Acta. Octubre 2013, Vol. 800, páginas 103 - 110. *

Also Published As

Publication number Publication date
RU2657578C2 (ru) 2018-06-14
PT2952203T (pt) 2016-11-23
CA2890642A1 (en) 2015-11-29
JP2018115210A (ja) 2018-07-26
CN105315362A (zh) 2016-02-10
MX362869B (es) 2019-02-20
KR101960729B1 (ko) 2019-03-21
US20170000855A9 (en) 2017-01-05
ZA201503539B (en) 2017-01-25
NZ708537A (en) 2017-06-30
EP2952203B1 (en) 2016-10-26
ES2524516B1 (es) 2015-03-31
BR102015012091A8 (pt) 2021-03-16
KR20160024348A (ko) 2016-03-04
CN105315362B (zh) 2019-10-25
HUE031823T2 (en) 2017-08-28
BR102015012091A2 (pt) 2016-01-05
JP2020111614A (ja) 2020-07-27
CL2015001446A1 (es) 2016-05-13
TWI607018B (zh) 2017-12-01
CA2890642C (en) 2019-02-12
MX2015006407A (es) 2015-11-30
AR100618A1 (es) 2016-10-19
MY171771A (en) 2019-10-29
US10350274B2 (en) 2019-07-16
IL238898B (en) 2018-01-31
EP2952203A1 (en) 2015-12-09
PL2952203T3 (pl) 2017-02-28
US20150343025A1 (en) 2015-12-03
RU2015118453A (ru) 2016-12-10
EP2952203B9 (en) 2018-03-14
JP2015224251A (ja) 2015-12-14
AU2015202413A1 (en) 2015-12-17
ES2601137T3 (es) 2017-02-14
ES2524516A1 (es) 2014-12-09
SG10201504137PA (en) 2015-12-30
TW201544510A (zh) 2015-12-01

Similar Documents

Publication Publication Date Title
EP2952203B9 (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
JP5744959B2 (ja) 解毒療法に使用するためのヒトアルブミンを高効率で得る方法
JPS6267032A (ja) 組換ヒトβ―インターフェロンを含有する医薬組成物及びその製造方法
EA025663B1 (ru) Композиции этанерцепта, стабилизированные ионами металлов
ES2272548T3 (es) Metodo para producir albumina de suero humano que implica un etapa de tratamiento con calor.
Tanabe et al. Denatured human α-defensin attenuates the bactericidal activity and the stability against enzymatic digestion
JPH0381290A (ja) 精製されたアルブミン溶液の製造方法
KR100827750B1 (ko) 인체 혈청알부민 다량체의 단량체화 방법
US20180250368A1 (en) Liquid composition of human albumin for therapeutic use
JP4798831B2 (ja) ヒト血清アルブミンのミスホールディングを抑制する方法
AU2024237593A1 (en) Method for the preparation of albumin solutions and uses related thereto and thereof
Ebrahim-Damavandi et al. Reducing allergenicity of bovine beta lactoglobulin throughout Cu complexes
Vahidzadeh et al. Studies on the interaction of colchicine and human serum albumin by the measurement of zeta-potential
Lang et al. Chemical characterization of human urine albumin in proteinuria
BR112020001363A2 (pt) formulações de hemopexina
Harrington Age and cataract-related degradation of crystallins in human lenses
CS256710B1 (en) Method of albumin extraction from cohne fraction 4

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JORQUERA NIETO, JUAN IGNACIO; ORTIZ FERNANDEZ, ANA MARIA AND COSTA RIEROLA, MONTSERRAT

FGA Letters patent sealed or granted (standard patent)